Underscore VC is primarily a B2B software investor with about 50% of our investments in B2B vertical SaaS and 50% in Fintech and Emerging Technology companies.
While we steer clear of biotech and anything requiring FDA approval, we’re interested in healthcare and life sciences and have backed companies such as H1 and TetraScience that sit at the intersection of SaaS and healthtech.
You’ll note that the Underscore portfolio is fairly diversified across B2B software. This is because, as early-stage investors, we don’t see our role as predictors of the future. We leave it to bold founders to envision the next generation of iconic software companies.
That said, we don’t back companies or even ideas. We back people. People who are uniquely qualified and purposeful about solving impactful problems. That’s why it will always be about you. Just ask our founders.
